Microarray Scanners Market Report 2025

The microarray scanners market size has grown strongly in recent years. It will grow from $0.94 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increased genomic research, pharmaceutical industry growth, academic and research institutes, diagnostic applications, high-throughput screening.

The microarray scanners market size is expected to see strong growth in the next few years. It will grow to $1.38 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing focus on pharmacogenomics, increasing demand for biobanking, increased focus on infectious disease research, increasing demand for diagnostic laboratories, growing application areas of microarrays. Major trends in the forecast period include focus on cancer research, technological innovation, and strategic partnerships.

The anticipated growth in the microarray scanner market is expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, characterized by lasting three months or more and having the potential to worsen over time, can be effectively studied using microarray scanners. These devices enable the assessment of gene expression patterns, allowing researchers to delve into the molecular mechanisms underlying chronic diseases and identify potential biomarkers for diagnosis, prognosis, and treatment. According to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, the global population with chronic diseases is projected to reach 142.66 million by 2050, a significant increase from 71.522 million in 2020. Thus, the growing prevalence of chronic diseases is a key driver for the expansion of the microarray scanner market.

The rising health expenditure is anticipated to drive the growth of the microarray scanners market in the coming years. Health expenditure refers to the total amount of public and private resources allocated to health-related products and services over a specific period, typically assessed annually. Increased spending on health enhances the expansion and refinement of genomics research, leading to advancements in healthcare and personalized therapies. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure in the UK rose by 5.6% in nominal terms in 2023, reaching approximately £292 billion. Government-financed healthcare expenditure also increased to around £239 billion. As a result, the growing health expenditure is expected to positively impact the microarray scanner market.

Product innovations are a significant trend gaining traction in the microarray scanners market. Leading companies in this sector are focusing on developing cutting-edge products to maintain their competitive edge. For example, in June 2023, MARGenomics, a Spain-based company, launched the Applied Biosystems GeneChip 3000 Dx v2, an advanced microarray platform representing a major advancement in microarray technology. This platform is notable for being the first in Europe and the United States to receive regulatory approval for diagnostic purposes, highlighting its potential impact on clinical diagnostics and research. With its capability to deliver high-resolution genomic data, it is set to enhance personalized medicine approaches across various therapeutic areas.

Major players in the microarray scanner market are directing their focus on product innovations, specifically in the development of chromosomal microarray scanners, to better cater to the needs of their existing customer base. Chromosomal microarray scanners are sophisticated laboratory instruments designed for high-throughput DNA sample analysis, with a specific emphasis on detecting chromosomal abnormalities. For example, in August 2023, Thermo Fisher Scientific Inc., a US-based manufacturer of microarray scanners and other analytical instruments, launched the Applied Biosystems CytoScan HD Accel array. This array offers the industry's fastest chromosomal microarray analytical methodology and enhanced coverage, scanning the entire human genome and providing increased coverage in over 5,000 crucial genomic areas. The Applied Biosystems CytoScan HD Accel array contributes valuable insights into chromosomal variations applicable to a wide range of prenatal, postnatal, and cancer research applications.

In January 2022, Illumina Inc., a US-based biotechnology company specializing in microarray scanners, entered into a collaboration with SomaLogic, a US-based clinical diagnostics company. This collaboration aims to expedite next-generation sequencing into Proteomics and initiate a multi-year development effort to integrate SomaLogic's protein target volume with Illumina's sequencing technologies, creating a comprehensive end-to-end NGS workflow solution.

Major companies operating in the microarray scanners market include F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., GE Healthcare Life Sciences, Hitachi High-Tech Corporation, Innopsys Inc., PerkinElmer Inc., VWR International LLC, Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Tecan Group AG, Huron Technologies International Inc., Miltenyi Biotec B.V. & Co. KG, GVS S.p.A., Luminex Corporation, Molecular Devices LLC, CapitalBio Technology Inc., Berthold Technologies GmbH & Co. KG, RayBiotech Inc., Scienion AG, Oxford Gene Technology IP Limited, Applied Microarrays Inc., Arrayit Corporation, Meridian Bioscience Inc., Montreal Biotech Inc.

North America was the largest region in the microarray scanners market in 2024. The regions covered in the microarray scanners market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microarray scanners market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Microarray scanners play a crucial role in molecular biology and genetics research, specifically for the analysis of microarrays. Microarrays are arrays of microscopic spots containing immobilized DNA, RNA, proteins, or other molecules on solid surfaces such as glass slides or silicon chips. These scanners are utilized to measure the fluorescent regions of DNA microarrays, providing detailed insights into the simultaneous activity of numerous genes.

The primary product categories of microarray scanners include fluorescence microarray scanners, charge-coupled device microarray scanners, colorimetric microarray scanners, and others. Fluorescence microarray scanners are specialized instruments designed for the detection and capture of fluorescent signals emitted by molecules labeled with fluorescence on microarrays. Microarray scanners utilize various technologies, including slide-based and gel-based approaches, with applications spanning gene expression, drug discovery, and more. The end users of these scanners are diverse and include hospitals, diagnostic laboratories, pharmaceutical and biotechnology companies, as well as academic and research institutes.

The microarray scanners market research report is one of a series of new reports that provides microarray scanners market statistics, including microarray scanners industry global market size, regional shares, competitors with a microarray scanners market share, detailed microarray scanners market segments, market trends and opportunities, and any further data you may need to thrive in the microarray scanners industry. This microarray scanner market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The microarray scanners market consists of sales of microarray slides, microarray printing and labeling kit, microarray scanners software and analysis tools, and microarray wash stations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.